Therapeutic Response Statement (Sensitivity) Deprecated
This therapeutic response statement Supports the relationship that ER positive and HER2-negative status confers therapeutic sensitivity to Fulvestrant, Palbociclib in patients with Invasive Breast Carcinoma.
The Republic of Ireland's Health Service Executive (HSE) has approved palbociclib in combination with fulvestrant as a treatment option for the treatment of patients who are women with (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer who have received prior endocrine therapy.
This statement is based on a regulatory approval from the Health Service Executive:
Treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer in combination with fulvestrant in women who have received prior endocrine therapy
Citation
Contributions
| Date | Contributor | Description |
|---|---|---|
| 2024-01-16 | Van Allen lab | Adding HSE approvals for reimbursement to database |
| 2018-06-01 | Health Service Executive | Indication approved for reimbursement. |